---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-101816"
form_type: "8-K"
ticker: "TBPH"
cik: "0001583107"
company_name: "Theravance Biopharma, Inc."
filed_at: "2024-09-23T23:59:59+00:00"
generated_at: "2026-05-31T02:25:54.839714+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Theravance Biopharma settles YUPELRI patent litigation; Qilu generic entry delayed until April 2039

## Summary
- Settlement resolves Hatch-Waxman patent litigation over YUPELRI (revefenacin) with Qilu.
- Qilu granted royalty-free license to market generic revfenacin on or after April 23, 2039.
- Settlement subject to review by U.S. DOJ and FTC as required by law.
- Patent litigation against three other ANDA filers (Cipla, Eugia, Mankind) remains pending.

## SEC filing metadata
- accession: 0001104659-24-101816
- form_type: 8-K
- ticker: TBPH
- cik: 0001583107
- company_name: Theravance Biopharma, Inc.
- filed_at: 2024-09-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583107/000110465924101816/0001104659-24-101816-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583107/000110465924101816/tm2424315d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-101816
- JSON: https://secwatch.observer/filing/0001104659-24-101816.json
- Plain text: https://secwatch.observer/filing/0001104659-24-101816.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.